Designer benzodiazepines: A new challenge

Affiliations

Bjoern Moosmann et al. World Psychiatry.2015 Jun.

.2015 Jun;14(2):248.

doi: 10.1002/wps.20236.

¹ Institute of Forensic Medicine, Forensic Toxicology, Medical Center, University of Freiburg, Germany.
² Hermann Staudinger Graduate School, University of Freiburg, Germany.
³ Basingstoke, UK.

No abstract available

References

1. Schifano F, Orsolini L, Papanti GD, et al. Novel psychoactive substances of interest for psychiatry. World Psychiatry. 2015;14:15–26. - PMC - PubMed
1. Moosmann B, Bisel P, Auwärter V. Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics. Drug Test Anal. 2014;6:757–63. - PubMed
1. Moosmann B, Huppertz LM, Hutter M, et al. Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics. J Mass Spectrom. 2013;48:1150–9. - PubMed
1. Moosmann B, Hutter M, Huppertz LM, et al. Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine. Forensic Toxicol. 2013;31:263–71.
1. Sternbach LH, Randall LO, Banziger R. Structure-activity relationships in the 1,4-benzodiazepine series. In: Burger A, et al., editors. Drugs affecting the central nervous system. London: Edward Arnold; 1968. pp. 237–64.